The latest announcement is out from Scancell Holdings ( (GB:SCLP) ).
Scancell Holdings has announced a partnership with the NHS Cancer Vaccine Launch Pad to fast-track access for NHS patients into the fourth cohort of its Phase 2 clinical SCOPE study. This study will evaluate the intradermal administration of Scancell’s iSCIB1+, a second-generation DNA cancer vaccine, in patients with advanced melanoma. This collaboration marks Scancell as the first British company to join the CVLP, and iSCIB1+ as the first DNA vaccine in this initiative. The partnership aims to expedite patient access to potentially life-saving treatments and accelerate the clinical development of Scancell’s novel cancer vaccine, which has shown promising efficacy and long-term survival benefits in early trials.
Spark’s Take on GB:SCLP Stock
According to Spark, TipRanks’ AI Analyst, GB:SCLP is a Neutral.
Scancell Holdings’ overall stock score is heavily weighted by its poor financial performance, which is characterized by zero revenue and significant losses. However, the recent positive clinical trial data and strategic developments in cancer vaccine trials provide a counterbalance, indicating potential for future growth. Technical indicators suggest a bearish trend, although the stock is nearing oversold territory, which might indicate a potential rebound. Valuation metrics remain unattractive due to ongoing financial losses. Overall, while there are promising developments in the pipeline, the company’s current financial challenges necessitate caution.
To see Spark’s full report on GB:SCLP stock, click here.
More about Scancell Holdings
Scancell Holdings Plc is a clinical-stage biotechnology company specializing in the development of immunotherapies aimed at achieving a cancer-free future. The company focuses on creating tumor-targeted off-the-shelf vaccines that offer durable systemic immune responses with favorable safety profiles. Scancell’s lead product, iSCIB1+, is a DNA vaccine currently being tested in a phase 2 study for first-line melanoma treatment. Additionally, Scancell is developing a pipeline of high-affinity antibodies targeting tumor-specific glycans, with some being developed in collaboration with major biopharma partners.
YTD Price Performance: -23.26%
Average Trading Volume: 718,976
Technical Sentiment Signal: Strong Buy
Current Market Cap: £85.53M
Learn more about SCLP stock on TipRanks’ Stock Analysis page.